Dr. Reddy's Signs Commercialization, License Deals for Bio-Thera Biosimilars in Southeast Asia

MT Newswires Live

Mar 28, 2025

Dr. Reddy's Laboratories (RDY) signed commercialization and license agreements with Bio-Thera Solutions for biosimilars BAT2206 and BAT2506 in Southeast Asia, Bio-Thera said Thursday.

Under the agreements, Bio-Thera will still oversee the development, manufacturing, and supply of the drugs, while Dr. Reddy's will manage the regulatory approval process and commercialization in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.

Dr. Reddy's will also receive exclusive commercial rights to BAT 2206 in Colombia, according to Bio-Thera.

The company said BAT2206 is a proposed biosimilar to Jansen's Stelara, which has been approved in the EU for the treatment of a number of conditions, including moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis in adults.

BAT2506 is a proposed golimumab biosimilar to Simponi, which has been approved in the US for a number of conditions, including severe rheumatoid arthritis and active psoriatic arthritis, Bio-Thera said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522587951"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522587951\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522587951?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-28 01:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522587951","market":"sh","top_or_hot":-1,"title":"Dr. Reddy's Signs Commercialization, License Deals for Bio-Thera Biosimilars in Southeast Asia","media":"MT Newswires Live","content":"<html><body><p> Dr. Reddy's Laboratories (RDY) signed commercialization and license agreements with Bio-Thera Solutions for biosimilars BAT2206 and BAT2506 in Southeast Asia, Bio-Thera said Thursday.</p><p>Under the agreements, Bio-Thera will still oversee the development, manufacturing, and supply of the drugs, while Dr. Reddy's will manage the regulatory approval process and commercialization in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.</p><p>Dr. Reddy's will also receive exclusive commercial rights to BAT 2206 in Colombia, according to Bio-Thera.</p><p>The company said BAT2206 is a proposed biosimilar to Jansen's Stelara, which has been approved in the EU for the treatment of a number of conditions, including moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis in adults.</p><p>BAT2506 is a proposed golimumab biosimilar to Simponi, which has been approved in the US for a number of conditions, including severe rheumatoid arthritis and active psoriatic arthritis, Bio-Thera said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dr. Reddy's Signs Commercialization, License Deals for Bio-Thera Biosimilars in Southeast Asia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDr. Reddy's Signs Commercialization, License Deals for Bio-Thera Biosimilars in Southeast Asia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-28 01:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dr. Reddy's Laboratories (RDY) signed commercialization and license agreements with Bio-Thera Solutions for biosimilars BAT2206 and BAT2506 in Southeast Asia, Bio-Thera said Thursday.</p><p>Under the agreements, Bio-Thera will still oversee the development, manufacturing, and supply of the drugs, while Dr. Reddy's will manage the regulatory approval process and commercialization in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.</p><p>Dr. Reddy's will also receive exclusive commercial rights to BAT 2206 in Colombia, according to Bio-Thera.</p><p>The company said BAT2206 is a proposed biosimilar to Jansen's Stelara, which has been approved in the EU for the treatment of a number of conditions, including moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis in adults.</p><p>BAT2506 is a proposed golimumab biosimilar to Simponi, which has been approved in the US for a number of conditions, including severe rheumatoid arthritis and active psoriatic arthritis, Bio-Thera said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348744763.USD","symbol_name":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2522587951","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522587951","pubTimestamp":1743097026,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dr. Reddy's Laboratories  signed commercialization and license agreements with Bio-Thera Solutions for biosimilars BAT2206 and BAT2506 in Southeast Asia, Bio-Thera said Thursday.Under the agreements, Bio-Thera will still oversee the development, manufacturing, and supply of the drugs, while Dr. Reddy's will manage the regulatory approval process and commercialization in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.Dr. Reddy's will also receive exclusive commercial rights to BAT 2206 in Colombia, according to Bio-Thera.The company said BAT2206 is a proposed biosimilar to Jansen's Stelara, which has been approved in the EU for the treatment of a number of conditions, including moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis in adults.BAT2506 is a proposed golimumab biosimilar to Simponi, which has been approved in the US for a number of conditions, including sever","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","BK4557":"大麻股","RDY":"如瑞迪博士","BK4523":"印度概念","RDY.AU":"READYTECH HOLDINGS LTD","BK4532":"文艺复兴科技持仓","BK4596":"哈里斯概念","BK4007":"制药","BK7016":"应用软件"},"translate_title":"Dr.Reddy's签署Bio-Thera生物仿制药在东南亚的商业化和许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDY.AU":1,"RDY":0.9},"content_text":"Dr. Reddy's Laboratories (RDY) signed commercialization and license agreements with Bio-Thera Solutions for biosimilars BAT2206 and BAT2506 in Southeast Asia, Bio-Thera said Thursday.Under the agreements, Bio-Thera will still oversee the development, manufacturing, and supply of the drugs, while Dr. Reddy's will manage the regulatory approval process and commercialization in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.Dr. Reddy's will also receive exclusive commercial rights to BAT 2206 in Colombia, according to Bio-Thera.The company said BAT2206 is a proposed biosimilar to Jansen's Stelara, which has been approved in the EU for the treatment of a number of conditions, including moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis in adults.BAT2506 is a proposed golimumab biosimilar to Simponi, which has been approved in the US for a number of conditions, including severe rheumatoid arthritis and active psoriatic arthritis, Bio-Thera said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}